BIOMAT Database Logo BIOMAT Database Logo

Juvenile chronic myeloid leukaemia and alpha-interferon. 1989

M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D054438 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL). Atypical Chronic Myeloid Leukemia,Chronic Myeloid Leukemia, Atypical,Leukemia, Myeloid, Philadelphia-Negative,Myeloid Leukemia, Philadelphia-Negative,Leukemia, Myelogenous, Ph1 Negative,Leukemia, Myelogenous, Ph1-Negative,Leukemia, Myeloid, Chronic, Atypical,Leukemia, Myeloid, Ph1 Negative,Leukemia, Myeloid, Ph1-Negative,Leukemia, Myeloid, Philadelphia Negative,Myelogenous Leukemia, Ph1-Negative,Myeloid Leukemia, Ph1-Negative,Leukemia, Ph1-Negative Myelogenous,Leukemia, Ph1-Negative Myeloid,Leukemia, Philadelphia-Negative Myeloid,Leukemias, Ph1-Negative Myelogenous,Leukemias, Ph1-Negative Myeloid,Leukemias, Philadelphia-Negative Myeloid,Myelogenous Leukemia, Ph1 Negative,Myelogenous Leukemias, Ph1-Negative,Myeloid Leukemia, Ph1 Negative,Myeloid Leukemia, Philadelphia Negative,Myeloid Leukemias, Ph1-Negative,Myeloid Leukemias, Philadelphia-Negative,Ph1-Negative Myelogenous Leukemia,Ph1-Negative Myelogenous Leukemias,Ph1-Negative Myeloid Leukemia,Ph1-Negative Myeloid Leukemias,Philadelphia-Negative Myeloid Leukemia,Philadelphia-Negative Myeloid Leukemias

Related Publications

M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Interferon-alpha 1 for chronic myeloid leukaemia.
November 1995, Lancet (London, England),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Juvenile chronic myeloid leukaemia.
May 1970, Lancet (London, England),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Juvenile chronic myeloid leukaemia.
May 1970, Lancet (London, England),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Juvenile chronic myeloid leukaemia.
March 1970, Lancet (London, England),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia.
July 1991, British journal of haematology,
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Case of juvenile chronic myeloid leukaemia.
February 1970, Lancet (London, England),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Hypocholesterolaemia in juvenile chronic myeloid leukaemia.
March 1988, European journal of haematology,
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia.
February 2006, Nephrology (Carlton, Vic.),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia.
June 1989, Lancet (London, England),
M Aricò, and L Nespoli, and D Caselli, and F Bonetti, and F A Porta, and G R Burgio
[Alpha interferon in children with Philadelphia chromosome-positive chronic myeloid-leukaemia].
May 2005, La Tunisie medicale,
Copied contents to your clipboard!